<p>目前在 <strong>ARK Invest</strong> 內部展開的大規模輪換表明，<strong>Cathie Wood</strong> 認為 2026 年將是基因組革命的決定性亮相。</p>
<ul>
<li><strong>PACB 股票上漲。 查看圖表和價格走勢。</strong></li>
</ul>
<p>隨着 2025 年的結束，ARK 積極削減 特斯拉公司 (NASDAQ: TSLA) 和 <strong>Rocket Lab Corp.</strong> (NASDAQ: RKLB) 等傳統贏家，以資助對基因編輯先驅的數百萬美元的增持。</p>
<p><strong>下一步閲讀：</strong> Palantir：從 Meme 股票到 2025 年的市場領導者</p>
<p>ARK Invest 特別增持了 <strong>CRISPR Therapeutics AG</strong> (NASDAQ: CRSP)、<strong>Intellia Therapeutics, Inc.</strong> (NASDAQ: NTLA)、<strong>Beam Therapeutics, Inc.</strong> (NASDAQ: BEAM) 和 <strong>Pacific Biosciences of California Inc.</strong> (NASDAQ: PACB)，以迎接年底的到來。</p>
<h2><strong>策略</strong></h2>
<p>Wood 的理論建立在人工智能與可編程生物學的結合之上。今年早些時候，Wood 強調了人工智能在醫療保健中的變革潛力，稱其為人工智能的 最深遠應用。</p>
<p>根據 Ark 的多組學飛輪 框架，人工智能加速了多組學的各個方面，從生成生物數據到診斷疾病和開發新藥。</p>
<p>“更智能的算法使基因測序更快；更便宜的測序為人工智能提供了更多學習數據；基因編輯的突破可以為新療法打開大門，” Wood 解釋道。</p>
<h2><strong>持股</strong></h2>
<p>到 2025 年底，ARK 將 CRISPR Therapeutics 的權重提高到其旗艦 <strong>ARKK 創新基金</strong> (BATS: ARKK) 的 5% 以上，Beam Therapeutics 增長到 ARKK 的 3.41%，Twist 佔 2%，Intellia 佔同一基金的 1.14%。</p>
<p>Ark Invest 還擁有 <strong>Ark Genomic Revolution Fund</strong> (BATS: ARKG)，專注於投資與基因組革命主題相關的各個行業的公司，包括醫療保健和信息技術。</p>
<p><strong>下一步閲讀：</strong></p>
<ul>
<li>金屬表現如 Meme 股票——關於重大白銀保證金追繳的未確認傳聞</li>
</ul>
<p><em>照片來源：Shutterstock</em></p>

CRISPR治療

<p>Cathie Wood 的 ARK Invest 正在轉向基因組股票，預計到 2026 年將迎來重大的基因組革命。該公司已經出售了特斯拉等傳統股票，重金投資於基因編輯公司，如 CRISPR Therapeutics、Beam Therapeutics 和 Pacific Biosciences。Wood 強調了人工智能與生物學之間的協同作用，預測人工智能的進步將提升基因測序和藥物開發的效率。到 2025 年底，ARK 在這些公司的持股將在其旗艦 ARKK 創新基金和 Ark 基因組革命基金中顯著增加</p>

<p>The massive rotation currently unfolding within <strong>ARK Invest</strong> suggests that <strong>Cathie Wood</strong> thinks 2026 will be the definitive coming-out party for the genomic revolution.</p>
<div class="lb-trans"><p>目前在 <strong>ARK Invest</strong> 內部展開的大規模輪換表明，<strong>Cathie Wood</strong> 認為 2026 年將是基因組革命的決定性亮相。</p>
</div><ul>
<li><strong>PACB stock is up. See the chart and price action here.</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>PACB 股票上漲。 查看圖表和價格走勢。</strong></li>
</ul>
</div><p>As 2025 draws to a close, ARK aggressively trimmed legacy winners such as <strong>Tesla, Inc.</strong> (NASDAQ: TSLA) and <strong>Rocket Lab Corp.</strong> (NASDAQ: RKLB) to fund a multi-million dollar accumulation of gene-editing pioneers.</p>
<div class="lb-trans"><p>隨着 2025 年的結束，ARK 積極削減 特斯拉公司 (NASDAQ: TSLA) 和 <strong>Rocket Lab Corp.</strong> (NASDAQ: RKLB) 等傳統贏家，以資助對基因編輯先驅的數百萬美元的增持。</p>
</div><p><strong>Read Next:</strong> Palantir: From Meme Stock To Market Leader In 2025</p>
<div class="lb-trans"><p><strong>下一步閲讀：</strong> Palantir：從 Meme 股票到 2025 年的市場領導者</p>
</div><p>ARK Invest has been specifically loading up on shares of <strong>CRISPR Therapeutics AG</strong> (NASDAQ: CRSP), <strong>Intellia Therapeutics, Inc.</strong> (NASDAQ: NTLA), <strong>Beam Therapeutics, Inc.</strong> (NASDAQ: BEAM) and <strong>Pacific Biosciences of California Inc.</strong> (NASDAQ: PACB) heading into the end of the year.</p>
<div class="lb-trans"><p>ARK Invest 特別增持了 <strong>CRISPR Therapeutics AG</strong> (NASDAQ: CRSP)、<strong>Intellia Therapeutics, Inc.</strong> (NASDAQ: NTLA)、<strong>Beam Therapeutics, Inc.</strong> (NASDAQ: BEAM) 和 <strong>Pacific Biosciences of California Inc.</strong> (NASDAQ: PACB)，以迎接年底的到來。</p>
</div><h2><strong>The Strategy</strong></h2>
<div class="lb-trans"><h2><strong>策略</strong></h2>
</div><p>Wood's thesis is built on the combination of artificial intelligence and programmable biology. Earlier this year, Wood highlighted the transformative potential of AI in health care, calling it the most profound application of artificial intelligence.</p>
<div class="lb-trans"><p>Wood 的理論建立在人工智能與可編程生物學的結合之上。今年早些時候，Wood 強調了人工智能在醫療保健中的變革潛力，稱其為人工智能的 最深遠應用。</p>
</div><p>According to Ark’s multiomics flywheel framework, AI accelerated all aspects of multiomics from generating biological data to diagnosing diseases and developing new drugs.</p>
<div class="lb-trans"><p>根據 Ark 的多組學飛輪 框架，人工智能加速了多組學的各個方面，從生成生物數據到診斷疾病和開發新藥。</p>
</div><p>“Smarter algorithms make gene sequencing faster; cheaper sequencing gives AI more data to learn from; and breakthroughs in gene editing can open the door to new treatments,” Wood explained.</p>
<div class="lb-trans"><p>“更智能的算法使基因測序更快；更便宜的測序為人工智能提供了更多學習數據；基因編輯的突破可以為新療法打開大門，” Wood 解釋道。</p>
</div><h2><strong>The Holdings</strong></h2>
<div class="lb-trans"><h2><strong>持股</strong></h2>
</div><p>By late December 2025, ARK increased its weight in CRISPR Therapeutics to over 5% of its flagship <strong>ARKK Innovation Fund</strong> (BATS: ARKK), Beam Therapeutics grew to 3.41% of ARKK, Twist accounted for 2% and Intellia was 1.14% of the same fund.</p>
<div class="lb-trans"><p>到 2025 年底，ARK 將 CRISPR Therapeutics 的權重提高到其旗艦 <strong>ARKK 創新基金</strong> (BATS: ARKK) 的 5% 以上，Beam Therapeutics 增長到 ARKK 的 3.41%，Twist 佔 2%，Intellia 佔同一基金的 1.14%。</p>
</div><p>Ark Invest also has the <strong>Ark Genomic Revolution Fund</strong> (BATS: ARKG) dedicated to investing in companies across sectors, including health care and information technology, that are relevant to the theme of the genomics revolution.</p>
<div class="lb-trans"><p>Ark Invest 還擁有 <strong>Ark Genomic Revolution Fund</strong> (BATS: ARKG)，專注於投資與基因組革命主題相關的各個行業的公司，包括醫療保健和信息技術。</p>
</div><p><strong>Read Next:</strong></p>
<div class="lb-trans"><p><strong>下一步閲讀：</strong></p>
</div><ul>
<li>Metals Acting Like Meme Stocks—Unconfirmed Rumor Of Major Silver Margin Call</li>
</ul>
<div class="lb-trans"><ul>
<li>金屬表現如 Meme 股票——關於重大白銀保證金追繳的未確認傳聞</li>
</ul>
</div><p><em>Photo: Shutterstock</em></p>
<div class="lb-trans"><p><em>照片來源：Shutterstock</em></p>
</div>

Cathie Wood 的生物技術趨勢：Twist, Beam, CRISPR 最新的股票選擇